R&D costs for Gleevec | Knowledge Ecology International
▻http://keionline.org/node/1697
Novartis was not “the innovative force.” Not only was all the basic research done in academic institutions, but so were the initial clinical investigations that showed STI 571 to be specifically effective against CML cells in vitro and in vivo. In fact, it took a few years for Brian Druker, the investigator most responsible for these latter studies, to convince Novartis that it should invest in a crash program to develop Gleevec and to undertake large-scale clinical trials.
#glivec (ou en américain #gleevec) et les #coûts réels de la #recherche #pharma
#santé #cancer #inde #brevets